BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging
Phase 3
Completed
- Conditions
- Central Nervous System Diseases
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 343
- Registration Number
- NCT00623467
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇺🇸University of South Florida, Tampa, Florida, United States
🇦🇷Centro de Diagnóstico Dr. Enrique Rossi, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
Phase 2
Terminated
- Conditions
- Hemophilia A
- Interventions
- Biological: rFVIII-FS/pegylated liposomes (BAY79-4980)Biological: rFVIII-FS/WFI (BAY14-2222)
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 143
- Registration Number
- NCT00623727
Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 453
- Registration Number
- NCT00624130
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
Phase 3
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 84
- Registration Number
- NCT00623480
Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT00622479
Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1
- Registration Number
- NCT00621673
Sorafenib Dose Escalation in Renal Cell Carcinoma
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 83
- Registration Number
- NCT00618982
Aprotinin US Special Access Protocol
- Conditions
- Postoperative Hemorrhage
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Bayer
- Registration Number
- NCT00611845
Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients
Phase 1
Completed
- Conditions
- Advanced Cancer
- Interventions
- Drug: RDEA119
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 69
- Registration Number
- NCT00610194
- Locations
- 🇺🇸
TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸Roswell Park Cancer, Buffalo, New York, United States
🇺🇸UCHSC, Aurora, Colorado, United States
Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT00606125
© Copyright 2025. All Rights Reserved by MedPath